Knockdown of hypoxia-inducible factor 1-alpha (HIF1α) interferes with angiopoietin-like protein 2 (ANGPTL2) to attenuate high glucose-triggered hypoxia/reoxygenation injury in cardiomyocytes

Weiguo Chen a, Jianbang Wang a, Xihui Wang a, Pan Chang b, and Meng Liang a

aDepartment of Cardiology, The Second Affiliated Hospital of Xi’an Medical University, Xi’an, P.R. China; bExperimental Center, The Second Affiliated Hospital of Xi’an Medical University, Xi’an, P.R. China

ABSTRACT
To investigate the role of hypoxia-inducible factor 1-alpha (HIF1A) in hypoxia/reoxygenation (H/R) injury of cardiomyocytes induced by high glucose (HG). The in vitro model of coronary heart disease with diabetes was that H9c2 cells were stimulated by H/R and HG. Quantitative reverse transcription PCR (RT-qPCR) and Western blot analysis were used to detect the expression of HIF1A and angiopoietin-like protein 2 (ANGPTL2) in H9c2 cells. Cell viability and apoptosis were, respectively, estimated by Cell Counting Kit 8 (CCK-8) and TUNEL assays. Lactate dehydrogenase (LDH) activity, inflammation and oxidative stress were in turn detected by their commercial assay kits. Luciferase reporter assay and chromatin immunoprecipitation (ChIP) assay were used to confirm the association between HIF1A and ANGPTL2 promoter. The expression of nuclear factor E2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) pathway-related proteins and apoptosis-related proteins were also detected by Western blot analysis. As a result, ANGPTL2 expression was upregulated in H9c2 cells induced by HG or/and H/R, ANGPTL2 positively modulated HIF1A expression in H9c2 cells. HG or/and H/R suppressed the cell viability and promoted apoptosis, inflammatory response and oxidative stress levels in H9c2 cells. However, the knockdown of ANGPTL2 could reverse the above phenomena in H/R-stimulated-H9c2 cells through activation of Nrf2/HO-1 pathway. HIF1A transcriptionally activated ANGPTL2 expression. The effect of knockdown of ANGPTL2 on H/R triggered-H9c2 cells was weakened by HIF1A overexpression. In conclusion, knockdown of HIF1A downregulated ANGPTL2 to alleviate H/R injury in HG-induced H9c2 cells by activating the Nrf2/HO-1 pathway.

Introduction
Coronary heart disease generally refers to coronary atherosclerotic heart disease, in which the coronary artery vessels develop atherosclerotic lesions and cause lumen narrowing or obstruction, resulting in myocardial ischemia and hypoxia or necrosis [1]. In recent years, the incidence and mortality of coronary heart disease are increasing yearly, among which acute myocardial infarction (AMI) often shows a high disability rate and a high death rate [2,3]. One of the main manifestations of AMI is partial ischemia, defined as hypoxia and necrosis of local cardiomyocytes caused by AMI and coronary artery flow interruption. Early reperfusion therapy of hypoxic cardiomyocytes is the most effective therapy to save the dying myocardium [4]. Nevertheless, myocardial ischemia/reperfusion injury, a common type of myocardial injury in clinical practice, mainly occurs in reperfusion treatment of AMI [5] and can further cause malignant arrhythmias, cardiogenic shock and other serious concomitant symptoms to threaten the life of patients [6]. Therefore, active prevention and treatment is required [7,8].

Diabetes mellitus (DM) can significantly increase the morbidity and mortality rate of cardiovascular disease. Cardiovascular disease is not only the main complication of DM patients but also responsible for the death of DM patients [9]. Abnormal glucose metabolism caused by both DM and obesity can lead to the occurrence of cardiovascular disease, even in non-DM people. Postprandial glucose can also increase the risk of cardiovascular disease [10,11]. In addition to insulin resistance or hyperinsulinemia caused by abnormal blood glucose, DM...
patients are often accompanied by overweight or obese hyperlipidemia and hypertension, which are also risk factors for cardiovascular disease [12]. DM is considered to be an independent risk factor for cardiovascular disease [13]. Furthermore, type 2 (non-insulin-dependent) diabetes is related to a significantly increased risk of coronary heart disease and it is essential to manage cardiovascular risk factors in diabetic patients as aggressively as in nondiabetic patients with prior myocardial infarction [14].

Angiopoietin-like proteins (ANGPTLs) are a family of secretory glycoproteins that have been discovered in recent years. ANGPTL2 is a member of ANGPTLs and an inflammatory mediator mainly secreted by adipose tissue, vascular endothelial cells, monocytes or macrophages [15–17]. Studies have suggested that the normal expression of ANGPTL2 is conducive to the process of angiogenesis and tissue repair [18]. However, excessive expression of ANGPTL2 can cause chronic inflammatory response and irreversible tissue remodeling, leading to the occurrence of related diseases including obesity metabolic diseases, type 2 diabetes mellitus, atherosclerosis [15], tumors [19,20] and autoimmune diseases [21], etc. In ANGPTL2 knockout mouse, apoptosis of vascular endothelial senescent cells and promotion of endothelial repair can slow down the progression of atherosclerosis [22]. ANGPTL2 plays a promotive role in atherosclerosis by accelerating atherosclerosis calcification [23]. Recently, ANGPTL2 has been found to regulate the development of diabetes and its complications. ANGPTL2 upregulation is positively associated with the increased risk of cardiovascular events and death in patients with diabetes [24]. Study has found that the expression level of ANGPTL2 is significantly increased in glomeruli of diabetic nephropathy patients [25]. ANGPTL2 may be used as an indicator to evaluate the progression of diabetic nephropathy [26]. Animal experiment has found that the intake of exogenous ANGPTL2 protein can initiate the inflammatory response of corneal tissues and blood vessels in mice, leading to the formation of diabetic retinopathy to a certain extent [17]. However, the underlying mechanisms of the protective role of ANGPTL2 in hypoxia/reoxygenation (H/R) injury remain unclear.

Ischemia/reperfusion injury and H/R injury can increase the hypoxia-inducible factor 1-alpha (HIF1A) expression in H9c2 cells [27]. HIF1A expression is upregulated in H9c2 cells after high glucose (HG) treatment [28] and HIF1A knockdown can significantly reduce the apoptosis and inflammatory response of HG-treated H9c2 cells [29]. Inhibition of HIF1A improves abnormal glucose and lipid metabolism in HIF1A-overexpressed or Ang II/hypoxia-stimulated H9c2 cells [30]. JASPAR (https://jaspar.genereg.net/) predicts that the transcription factor hypoxia-inducible factor 1-alpha (HIF1A) binds to the ANGPTL2 promoter. However, the interaction between HIF1A and ANGPTL2 in HG-triggered HR injury in cardiomyocytes still needs to be explored.

Nuclear factor E2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) pathway has been reported to be involved in diabetes-related diseases. Diosgenin protects against diabetic peripheral neuropathy by the activation of Nrf2/HO-1 signaling pathway [31]. MitoQ alleviates the injury in brain microvascular endothelial cells (BMECs) induced by HG via activating Nrf2/HO-1 pathway [32]. Pterostilbene suppresses cardiac oxidative stress and inflammation in diabetic rats by activating the AMPK/Nrf2/HO-1 signaling pathway [33]. Inhibition of ANGPTL2 can alleviate the H/R injury in renal tubular epithelial cells by activating Nrf2/HO-1 pathway [34].

The current study investigates whether knockdown of the transcription factor HIF1A downregulates ANGPTL2 to alleviate HG-stimulated H/R injury in cardiomyocytes and aims to figure out whether the Nrf2/HO-1 pathway participates in this process. We detected the ANGPTL2 expression in HG-stimulated H/R injury in H9c2 cells. Subsequently, Cell Counting Kit 8 (CCK-8), Tunel and inflammation and oxidative stress-related detection kits were used to explore the effects of ANGPTL2 knockdown on the biological function of H9c2 cells and the reversible effect of HIF1A overexpression on the effects of ANGPTL2 knockdown. Western blot analysis was used to explore the effects of ANGPTL2 knockdown on the Nrf2/HO-1 pathway.
Materials and methods

Cell culture and treatment
Rat myocardial cell line (H9c2) was provided by the American Type Culture Collection (ATCC; CRL-1446™) and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% FBS, 100 U/ml penicillin G and 100 μg/mL streptomycin at 37°C with 5% CO₂. The H9c2 cells in our study were cultured in DMEM containing 5.5 mM glucose [normal glucose (NG)] or 30 mM glucose [high glucose (HG)] [35]. H9c2 cells were incubated under 95% N₂ and 5% CO₂ at 37°C for 6 h and then were removed to a normoxic chamber for 2 h to establish reoxygenation (H/R group). H9c2 cells were exposed to HG for 24 h, and then the above steps were repeated again (HG-H/R group). For mannitol (MA) group, H9c2 cells were cultured in DMEM containing 30 mM mannitol for 24 h [36].

Cell transfection
shRNA-NC, shRNA-ANGPTL2#1, shRNA-ANGPTL2#2, pcDNA3.1 and pcDNA3.1-HIF1A were synthesized by Genepharma. H9c2 cells induced by HG or H/R were seeded into a 6-well-plate (1×10⁵ cells/well) and transected with shRNA-NC, shRNA-ANGPTL2#1, shRNA-ANGPTL2#2, pcDNA3.1 and pcDNA3.1-HIF1A using Lipofectamine™ 2000 (Thermo Fisher Scientific, Inc.) at 37°C for 2 h, followed by another 24-h culture at 37°C for subsequent analysis.

Quantitative reverse transcription PCR (RT-qPCR)
The TRIzol reagent (Invitrogen) was used to isolate RNA from H9c2 cells. The total RNA was reverse transcribed into cDNA. RT-qPCR analysis was performed as per the instructions of SYBR Green Master Mix (Takara) on an FTC-3000TM System (Funglyn Biotech). GAPDH was chosen as an internal control for the levels of ANGPTL2 and HIF1A mRNA, respectively. Sequence information was listed here: ANGPTL2 forward, 5’-GCCACCAAGTGT CAGCCTCA-3’ and reverse, 5’-TGGACAGTAC CAAAC ATCCAAACATC-3’; HIF1A forward, 5’- TCTCCATCTCCTACCACATACA-3’ and reverse, 5’-TGCTCTGGTGGTGAGGCTGT-3’; GAPDH forward, 5’-GAATACTAGG ATGGTTGGCT-3’ and reverse, 5’-TCCCATTTCCAGCT CTCATA-3’. The 2⁻ΔΔCt method was performed to calculate the gene relative expression [37].

Western blot analysis
Total protein was extracted from H9c2 cells, of which the concentration was measured by BCA method. Protein samples in different groups were separated by 12% SDS-PAGE and transferred to activated PVDF membranes. Then, the membranes were blocked in 5% skim milk, followed by the incubation against the following primary antibodies overnight at 4°C: ANGPTL2 (ab199133; Abcam), Bcl2 (ab194583; Abcam), Bax (ab32503; Abcam), c-caspase9 (9507; Cell signaling technology), c-PARP (ab32064; Abcam), caspase9 (ab184786; Abcam), PARP (ab191217; Abcam), HIF1A (ab228649; Abcam), Nrf2 (ab92946; Abcam), HO-1 (ab68477; Abcam), GAPDH (ab181602; Abcam) and Lamin B1 (ab133741; Abcam). After being washed three times, the membranes were incubated with secondary antibodies (ab133470; Abcam) at room temperature for 1 h. The protein bands were developed by the enhanced chemiluminescence (ECL) system, and the density of each band was semi-quantified using ImageJ software (version 1.0; National Institutes of Health).

Cell Counting Kit-8 (CCK-8) assay
Cell viability was examined using CCK-8 (Beyotime, Nanjing, China) [38]. H9c2 cells from different groups were inoculated in a 96-well plate (5×10³ cells/well) and then cultured for 24 h at 37°C. Subsequently, 10 μl CCK-8 solution (cat. no. C0037; Beyotime) was added to each well and incubated at 37°C for 2 h. The cell viability was reflected at a wavelength of 450 nm using a microplate reader (Beckman Coulter, Inc.). The cell viability of NG group was 100%, the other groups referred to the NG group.

Detection of lactate dehydrogenase (LDH) and oxidative stress factors
Detection of malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px)
and lactate dehydrogenase (LDH) levels in the H9c2 cell culture medium from different groups was measured by MDA Assay kit (cat. no. S0131S; Beyotime), SOD Assay kit (cat. no. BMS222; Beyotime), High Throughput Glutathione Peroxidase Assay kit (cat. no. 7512–100-K; R&D Systems, Inc.) and LDH Assay Kit (cat. no. C0016; Beyotime), respectively.

**Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay**

H9c2 cells from different groups were obtained and fixed with 3.7% paraformaldehyde at room temperature for 30 min. Then, cells were detected by TUNEL apoptosis assay kit (Hilario Technology Co., Ltd.). Nuclei were stained by DAPI for 10 min at 37°C. Next, the apoptotic cells were captured using a fluorescence microscope.

**Enzyme-linked immunosorbent assay (ELISA)**

The expression levels of interleukin (IL)-6 (cat. no. PI330; Beyotime), tumor necrosis factor (TNF)-α (cat. no. PT518; Beyotime) and IL-1β (cat. no. PI305; Beyotime) in the H9c2 cell culture medium from each group were detected using ELISA kits according to the producer’s protocol.

**Dual luciferase reporter assay**

The interaction between ANGPTL2 promoter and HIF1A was verified by dual-luciferase reporter assay [39]. The fragments of ANGPTL2 promoter were amplified and cloned into pGL3.0-Basic Vector (Promega, Madison, WI, USA) to construct the luciferase reporter plasmids. H9c2 cells were co-transfected with ANGPTL2-WT or ANGPTL2-MUT, and pcDNA3.1-HIF1A or negative control using Lipofectamine 2000. After transfection for 48 h, cells were collected, and luciferase activities were analyzed by the Dual-Luciferase Assay Kit (Promega, Madison). Data were obtained as relative luciferase activity (Firefly luciferase activity/Renilla luciferase activity).

**Chromatin immunoprecipitation (ChIP) assay**

ChIP assay was used to determine that transcription factor HIF1A could interact with ANGPTL2 promoter [40]. Transcription factor HIF1A binding sites were assessed with the ChIP assay kit (cat. no. P2078; Beyotime) following the instructions of the manufacturer. The chromatin-protein complexes were separated by ultrasonication to obtain the DNA fragments, which were immunoprecipitated with HIF1A antibody HIF1A (ab228649; Abcam) or IgG (3900, Cell signaling technology) overnight at 4°C. The precipitated chromatin DNA was used as templates for real-time PCR.

**Statistical analysis**

GraphPad Prism 8.0 was used to perform statistical analysis and draw statistical graphs. Experimental results were expressed as mean ± standard deviation (SD). All experiment was repeated three times. The differences between the two groups were analyzed using the unpaired Student’s t-test and differences in multiple groups were analyzed by one-way analysis of variance and Tukey’s test. Differences were statistically significant when P < 0.05.

**Results**

**HG aggravates the up-regulation of ANGPTL2 in H/R-induced H9c2 (H/R-H9c2) cells**

The mRNA and protein levels of ANGPTL2 in H9c2 cells induced by HG or H/R or HG-H/R were, respectively, detected by RT-qPCR and Western blot analysis. The mRNA and protein levels of ANGPTL2 in HG-H9c2 cells and H/R-H9c2 cells were all increased compared with that in NG and MA groups. Meanwhile, the mRNA and protein levels of ANGPTL2 in HG-H/R group were significantly higher than that in HG group and H/R group, respectively (Figure 1 (a,b)). Overall, ANGPTL2 exhibited high expression in HG-H/R-induced H9c2 cells.

**Knockdown of ANGPTL2 increases the viability of HG-H/R stimulated H9c2 cells**

The mRNA and protein levels of ANGPTL2 in H9c2 cells induced by HG-H/R after transfection were determined by RT-qPCR and Western blot to confirm the transfection effects. After H/R-H9c2 cells were transfected with shRNA-
ANGPTL2#1 or shRNA-ANGPTL2#2, the expression of ANGPTL2 at mRNA level and protein level was decreased compared with that in shRNA-NC transfected cells and HG-H/R-induced cells (Figure 2(a,b)). The inhibition efficiency of shRNA-ANGPTL2#2 on ANGPTL2 expression was higher than that of shRNA-ANGPTL2#1, and shRNA-ANGPTL2#2 was selected for the subsequent study. To validate the functional role of ANGPTL2 in the viability of H9c2 cells, the cell viability and LDH expression in H9c2 cells after indicated treatment were analyzed by CCK-8 assay and LDH assay kit. As shown in Figure 2(c), H9c2 cell viability was decreased after H/R induction and was further reduced with the addition of HG induction, which was reversed by shRNA-ANGPTL2#2 transfection in HG-H/R-induced H9c2 cells. The result of Figure 2(d) also showed that LDH expression was increased in H9c2 cells treated with H/R and HG exposure further promoted the LDH expression in H/R-H9c2 cells. Also, knockdown of ANGPTL2 could reverse the changes of LDH expression induced by HG and H/R. Anyway, down-regulation of ANGPTL2 exacerbated the viability while lessening LDH expression in HG-H/R mediated H9c2 cells.

**Silencing of ANGPTL2 suppresses the apoptosis of HG-H/R induced H9c2 cells**

To validate the functional role of ANGPTL2 in the apoptosis of H9c2 cells after the indicated treatment, TUNEL assay and Western blot analysis were applied. Through TUNEL assay, it was observed that the apoptosis of H9c2 cells was aggravated by H/R and HG also enhanced the apoptosis of H/R-H9c2 cells (Figure 3(a)). Additionally, Western blot was used to analyze the protein levels of apoptosis-related factors. The results implied that Bcl2 expression was down-regulated, and Bax, c-caspase 9 and c-PARP expression were up-regulated in H/R-H9c2 cells, which was aggravated by HG (Figure 3(b)). However, the apoptosis in HG-H/R-induced H9c2 cells was reversed by deficiency of ANGPTL2. In short, inhibition of ANGPTL2 weakened the apoptotic capacity of HG-H/R-induced H9c2 cells.

**Knockdown of ANGPTL2 alleviates inflammatory response and oxidative stress levels of H9c2 cells upon exposure to H/R and HG.**

To validate the functional role of ANGPTL2 in the inflammatory response and oxidative stress of H9c2 cells, the levels of IL-1β, IL-6 and TNF-α

---

**Figure 1.** HG aggravates the up-regulation of ANGPTL2 in H/R-induced H9c2. The protein (a) and mRNA levels (b) of ANGPTL2 in H9c2 cells induced by H/R or HG-H/R were respectively determined by Western blot and RT-qPCR analysis. ***P < 0.001 vs. NG group. ###P < 0.001 vs. MA group. ####P < 0.001 vs. HG-H/R group.
were determined by ELISA assay, and oxidative stress levels were analyzed by respective commercial kits. As shown in Figure 4(a), levels of IL-1β, IL-6 and TNF-α were increased in H/R-H9c2 cells, which were enhanced again by HG treatment. MDA expression was increased, while SOD and GSH-Px expressions were decreased in H/R-H9c2 cells, which was promoted by HG (Figure 4(b)). All these results indicated that the inflammatory response and oxidative stress
levels in H/R-H9c2 cells were aggravated by HG. Moreover, ANGPTL2 insufficiency led to a decrease in the inflammatory response and oxidative stress in H9c2 cells triggered by HG-H/R. To be concluded, interference of ANGPTL2 played a suppressive role in the inflammatory response and oxidative stress in HG-H/R-induced H9c2 cells.

**HIF1A activates ANGPTL2 expression at the transcriptional level**

With the aid of JASPAR database, the interaction between HIF1A and ANGPTL2 promoter was predicted, and the binding site of HIF1A and ANGPTL2 promoter is shown in Figure 5(a). RT-qPCR and Western blot analysis suggested that HIF1A mRNA and protein levels were both increased in H9c2 cells transfected with pcDNA3.1-HIF1A compared with that in Control and pcDNA3.1 groups (Figure 5(b, c)). Further, dual-luciferase reporter assay indicated that the luciferase activities of ANGPTL2-WT were elevated when HIF1A was overexpressed (Figure 5(d)). Besides, ChIP assay confirmed the abundance of ANGPTL2 in HIF1A antibody, which verified the interaction between ANGPTL2 promoter and HIF1A (Figure 5(e)). Meanwhile, ANGPTL2 mRNA and protein levels were up-regulated in HG-H/R-induced H9c2 cells and down-regulated by knockdown of ANGPTL2. However, HIF1A overexpression could upregulate the ANGPTL2 expression, which attenuated the effect of shRNA-ANGPTL2 (Figure 5(f,g)). Briefly, HIF1A was a transcription activator of ANGPTL2.

**HIF1A overexpression reverses the protective effect of ANGPTL2 knockdown on HG-H/R-induced H9c2 cells.**

To validate whether HIF1A participated in the regulatory effects of ANGPTL2 on the malignant phenotype of HG-H/R mediated H9c2 cells, rescue experiments were implemented. Through CCK-8 assay and LDH assay kit, it was noticed that knockdown of ANGPTL2 improved the viability of HG-H/R-induced H9c2 cells and suppressed LDH levels (Figure 6(a,b)), which were reversed by HIF1A overexpression. In addition, the knockdown of ANGPTL2 reduced the apoptosis of HG-H/R-induced H9c2 cells, which was promoted by HIF1A overexpression (Figure 6(c, d)). As shown in Figure 6(e), the enhanced Bcl2...
expression and the decreased Bax, c-caspase9 and c-PARP expression due to knockdown of ANGPTL2 were all reversed by HIF1A overexpression. Similarly, the levels of TNF-α, IL-1β and IL-6 in HG-H/R-induced H9c2 cells were decreased by knockdown of ANGPTL2, which was increased by HIF1A overexpression (Figure 7(a)). HIF1A overexpression restored the decreased MDA expression and increased SOD and GSH-Px expression in HG/H/R-induced H9c2 cells transfected with shRNA-ANGPTL2 (Figure 7(b)). In summary, the protective role of ANGPTL2 inhibition in HG/H/R-induced H9c2 cells was abrogated by HIF1A up-regulation.

**Downregulation of ANGPTL2 activates the Nrf2/HO-1 pathway**

The protein levels of Nrf2/HO-1 pathway-related factors were detected by Western blot analysis. The results manifested that the expression Nrf2 (cytoplasm) was increased and expression of HO-1 and Nrf2 (nucleus) was reduced in HG-H/R-induced H9c2 cells, which was reversed by knockdown of ANGPTL2. In addition, HIF1A overexpression up-regulated the expression of Nrf2 (cytoplasm) and down-regulated the expression of HO-1 and Nrf2 (nucleus) in H/R-H9c2 cells transfected with shRNA-ANGPTL2 (Figure 8). Collectively, HIF1A-mediated ANGPTL2 inactivated the Nrf2/HO-1 pathway.

![Figure 4](image-url)  
*Figure 4.* Knockdown of ANGPTL2 alleviates inflammatory response and oxidative stress levels of H9c2 cells upon exposure to H/R and HG. (a) The levels of IL-1β, IL-6 and TNF-α in H/R-H9c2 or HG-H/R-H9c2 cells transfected with shRNA-ANGPTL2 were determined by ELISA kits. (b) The expression of MDA, SOD and GSH-Px in H/R-H9c2 cells or HG-H/R-H9c2 cells transfected with shRNA-ANGPTL2 were measured by corresponding kits. **P < 0.01 and ***P < 0.001 vs. NG group. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. MA group. @P < 0.05 and @@@P < 0.001 vs. HG-H/R group. & & & P < 0.001 vs. HG-H/R+ shRNA-NC group.*
**Discussion**

Myocardial infarction is primarily caused by continuous ischemia and hypoxia, resulting in cardiomyocyte death and excessively damaged myocardium. Therefore, timely and effective reduction of cardiomyocyte death has become the primary problem to be solved in the treatment of myocardial infarction. A recent study has shown that myocardial ischemia can lead to an imbalance between oxidation and antioxidation in the body, resulting in a large number of reactive oxygen species and oxidative stress injury [41]. Inflammation occurs after myocardial ischemia, leading to the release of inflammatory cytokines and a gradual increase on macrophage infiltration, which eventually leads to further myocardial injury [42]. Therefore, alleviating oxidative stress and inflammatory response is considered as potential and effective treatment methods for AMI injury.

Studies have shown that in AMI, inflammatory response runs through the whole pathophysiological process of myocardial ischemia injury. It plays a positive role in repairing myocardial injury to a certain extent and forming scar. However, excessive and continuous inflammatory reactions have a negative effect on myocardium, which can lead to ventricular remodeling in later stages, resulting in decreased cardiac function and accelerating the occurrence of heart failure [43, 44]. Studies have
shown that after myocardial ischemia-induced inflammation, endothelial cells produce IL-6, which stimulates the production and release of TNF-α and surface adhesion factor to aggravate the inflammatory response, ischemia injury, and lead to the occurrence and development of myocardial infarction [45,46]. In our study, the levels of IL-1β, IL-6 and TNF-α were increased in H/R-H9c2 cells and further increased with the addition of HG, which further presented that HG or H/R triggered the inflammatory response of H9c2 cells.

In the process of myocardial ischemia injury, oxygen free radicals can pass through the blood circulation. After AMI, the contents of oxygen free radicals in peripheral blood are increased, which significantly promotes oxidative stress levels, and suppresses the activity of antioxidant enzymes, as a result of which, continuous oxidative stress in

**Figure 6.** HIF1A overexpression reverses the inhibitory effect of knockdown of ANGPTL2 on HG-H/R induced H9c2 cell apoptosis. (a) Cell viability was appraised via CCK-8 assay. (b) LDH expression was examined by LDH assay kit. (c and d) The HG-H/R-H9c2 cell apoptosis using TUNEL assay. (e) The protein levels of apoptosis-related factors via Western blot. ***P < 0.001 vs. NG group. **#P < 0.01 vs. HG-H/R + shRNA-NC group. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. HG-H/R+ shRNA-ANGPTL2+ pcDNA3.1 group.
the body was caused [47]. MDA is a product of membrane lipid peroxidation, and its expression can directly reflect the degree of oxidative stress of cardiomyocytes [48]. SOD is an important barrier to inhibiting the damage to oxygen free radicals, which can reduce oxygen free radicals and protect cells from damage [48]. GSH-Px is a kind of peroxidase, which can reduce toxic peroxides to hydroxyl compounds, thus playing the role of protecting cardiomyocytes from the interference of oxides [49]. In our study, it was discovered that MDA expression was increased, while SOD and GSH-Px expression were decreased in H/R-H9c2 cells, which were aggravated by HG.

ANGPTL2 has been reported to regulate inflammation in multiple diseases, such as osteoarthritis [50,51], atherosclerosis [52], acute lung injury [53] and obesity [17]. ANGPTL2 promotes vascular inflammation and causes endothelial dysfunction and atherosclerotic progression via activation of pro-

**Figure 7.** HIF1A overexpression reverses the inhibitory effect of knockdown of ANGPTL2 on the inflammatory response and oxidative stress of HG-H/R stimulated H9c2 cells. (a) IL-1β, IL-6 and TNF-α levels in HG-H/R-H9c2 cells were tested by ELISA kits. (b) The expression of MDA, SOD and GSH-Px were analyzed by corresponding kits. ***P < 0.001 vs. NG group. ###P < 0.001 vs. HG-H/R + shRNA-NC group. @P < 0.05 and @@@P < 0.001 vs. HG-H/R + shRNA-ANGPTL2 group+ pcDNA3.1 group.
inflammatory signaling in endothelial cells, enhancement of macrophage infiltration [16]. Persistent autocrine/paracrine ANGPTL2 signaling in vascular tissues can lead to chronic inflammation and pathological tissue remodeling and accelerates the development of cardiovascular diseases [54]. ANGPTL2 can induce oxidative stress and creates a microenvironment, which enhances methylation of gene coding for DNA repair enzymes [55]. ANGPTL2 deficiency alleviates paraquate (PQ)-induced acute lung injury by reducing inflammation, oxidative stress and fibrosis [53]. In the present study, ANGPTL2 expression was increased in H/R-H9c2 cells, which was further promoted by HG. However, knockdown of ANGPTL2 alleviated the inflammatory response and oxidative stress through decreasing the levels of proinflammatory factors and regulating the expression of oxidative stress factors in HG-H/R-induced H9C2 cells. In addition, HIF1A activated ANGPTL2 expression at the transcriptional level, thereby weakening the protective effect of knockdown of ANGPTL2 on HG-H/R stimulated H9c2 cells.

HO-1 has been shown to play an important role in reducing oxidative stress-induced myocardial damage as an adaptive survival response, HO-1 expression can be regulated by Nrf2 signaling pathway under oxidative stress [56]. Nrf2 signaling plays an important role in protecting myocardial cells from oxidative stress injury [57]. Activated Nrf2 is released from Keap1 and translocated into the nucleus, thereby activating the transcription of the target gene HO-1 [58]. Nrf2/HO-1 signaling is a key pathway to regulate oxidative stress and plays an important role in AMI secondary injury. A study has shown that activation of the Nrf2/HO-1 pathway can alleviate myocardial injury after ischemia/reperfusion [59]. Nrf2/HO-1 pathway is an important antioxidant pathway. Upregulation of Nrf2 and HO-1 levels can alleviate oxidative stress injury caused by ischemia [60], and Nrf2/HO-1 directly regulates the apoptosis of cardiomyocytes by regulating oxidative stress or inflammatory response [61,62]. Adiponectin can improve cardiac hypertrophy and dysfunction caused by hyperglycemia via activating Nrf2-related pathways [63]. In this study, Nrf2/HO-1 pathway was suppressed in HG-H/R-induced H9c2 cells. Moreover, when HG-H/R-induced H9c2 cell injury was alleviated by suppressing apoptosis, inflammation and oxidative stress, Nrf2/HO-1 pathway was activated.

Conclusion

In summary, ANGPTL2 expression was increased in H/R-H9c2 cells, which was further promoted by HG. Knockdown of ANGPTL2 increased cell viability and suppressed apoptosis, inflammatory response and oxidative stress in HG-H/R-induced H9c2 cells through activating Nrf2/HO-1 pathway, which was reversed by HIF1A overexpression.
Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

Natural Science Foundation of Shaanxi Province (2021JQ-787); Health Science Foundation of Shaanxi Province (2021E023).

Availability of data and material

The experimental data will be available on the request.

References

[1] Di Angelantonio E, Thompson A, Wensley F, et al. Coronary heart disease. IARC scientific publications. 2011;(163):363–386.
[2] Saito I, Yamagishi K, Kokubo Y, et al. Association between mortality and incidence rates of coronary heart disease and stroke: the Japan Public Health Center-based prospective (JPHC) study. Int J Cardiol. 2016;222:281–286.
[3] Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–e245.
[4] Bin Z, Qian M, M F-Z, et al. Astragaloside ß's therapeutic effect on myocardial infarction via affecting autophagy and the mechanism study. Journal of Sichuan University (Medical science edition). 2021;52(2):222–228.
[5] Neri M, Riezzo I, Pascale N, et al. Ischemia/reperfusion injury following acute myocardial infarction: a critical issue for clinicians and forensic pathologists. Mediators Inflamm. 2017:2017:7018393.
[6] Ibañez B, Macaya C, Sánchez-Brunete V, et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD-CNlC) trial. Circulation. 2013;128(14):1495–1503.
[7] Tibaout M, Mekis D, Petrovic D. Pathophysiology of myocardial infarction and acute management strategies. Cardiovasc Hematol Agents Med Chem. 2017;14(3):150–159.
[8] Hausenloy DJ, Chilian W, Crea F, et al. The coronary circulation in acute myocardial ischaemia/reperfusion injury: a target for cardioprotection. Cardiovasc Res. 2019;115(7):1143–1155.
[9] Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics committee and stroke statistics subcommittee. Circulation. 2009;119(3):480–486.
[10] Crandall JP, Shamoon H, Cohen HW, et al. Postchallenge hyperglycemia in older adults is associated with increased cardiovascular risk profile. J Clin Endocrinol Metab. 2009;94(5):1595–1601.
[11] Lin HJ, Lee BC, Ho YL, et al. Postprandial glucose improves the risk prediction of cardiovascular death beyond the metabolic syndrome in the non-diabetic population. Diabetes Care. 2009;32(9):1721–1726.
[12] Reaven GM. The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr. 2006;83(6):1237–1247.
[13] Leif AA, Mather KJ, Clark CM. Diabetes and heart disease an evidence-driven guide to risk factors management in diabetes. Cardiol Rev. 2003;11(5):262–274.
[14] Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–234.
[15] Kadomatsu T, Endo M, Miyata K, et al. Diverse roles of ANGPTL2 in physiology and pathophysiology. Trends Endocrinol Metab. 2014;25(5):245–254.
[16] Horio E, Kadomatsu T, Miyata K, et al. Role of endothelial cell-derived angiopoietin2 in vascular inflammation leading to endothelial dysfunction and atherosclerosis progression. Arterioscler Thromb Vasc Biol. 2014;34(4):790–800.
[17] Tabata M, Kadomatsu T, Fukushima S, et al. Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. Cell Metab. 2009;10(3):178–188.
[18] Kadomatsu T, Tabata M, Oike Y. Angiopoietin-like proteins: emerging targets for treatment of obesity and related metabolic diseases. FEBS J. 2011;278(4):559–564.
[19] Aoi J, Endo M, Kadomatsu T, et al. Angiopoietin-like protein 2 is an important facilitator of inflammatory carcinogenesis and metastasis. Cancer Res. 2011;71(24):7502–7512.
[20] Endo M, Nakano M, Kadomatsu T, et al. Tumor cell-derived angiopoietin-like protein ANGPTL2 is a critical driver of metastasis. Cancer Res. 2012;72(7):1784–1794.
[21] Okada T, Tsukano H, Endo M, et al. Synoviocyte-derived angiopoietin-like protein 2 contributes to synovial chronic inflammation in rheumatoid arthritis. Am J Pathol. 2010;176(5):2309–2319.
[22] Caland L, Labbé P, Mamarbachi M, et al. Knockdown of angiopoietin-like 2 induces clearance of vascular endothelial senescent cells by apoptosis, promotes endothelial repair and slows atherosclerosis in mice. Aging (Albany NY). 2019;11(11):3832–3850.
[23] Jiao L, Zhuang Y, Jiang M, et al. Angiopoietin-like 2 has auxo-action in atherosclerosis by promoting atherosclerotic calcification. Int J Clin Exp Pathol. 2017;10(8):9084–9091.
[24] Gellen B, Thorin-Trescases N, Sosner P, et al. ANGPTL2 is associated with an increased risk of cardiovascular events and death in diabetic patients. Diabetologia. 2016;59(11):2321–2330.

[25] Yichao WU, Liu Z, Zeng C, et al. Glomerular gene expression profiles in patients with diabetic nephropathy. Chinese Journal of Nephrology Dialysis & Transplantation. 2004;13(6):503–511.

[26] Li Q, Gong W, Yang Z, et al. Serum Angptl2 levels are independently associated with albuminuria in type 2 diabetes. Diabetes Res Clin Pract. 2013;100(3):385–390.

[27] Zhang Y, Liu D, Hu H, et al. HIF-1α/BNIP3 signaling pathway-induced-autophagy plays protective role during myocardial ischemia-reperfusion injury. Biomed Pharmacother. 2019;120:109464.

[28] Li J, Yuan YQ, Zhang L, et al. Exogenous hydrogen sulfide protects against high glucose-induced apoptosis and oxidative stress by inhibiting the STAT3/HIF-1α pathway in H9c2 cardiomyocytes. Exp Ther Med. 2019;18(5):3948–3958.

[29] Pu J, Zhu S, Zhou D, et al. Propofol alleviates apoptosis induced by chronic high glucose exposure via regulation of HIF-1α in H9c2 cells. Oxid Med Cell Longev. 2019;2019:4824035.

[30] Zhu ZY, Wang F, Jia CH, et al. Apigenin-induced HIF-1α inhibitory effect improves abnormal glucolipid metabolism in AngII/hypoxia-stimulated or HIF-1α-overexpressed H9c2 cells. Phytomedicine. 2019;62:152713.

[31] Leng J, Li X, Tian H, et al. Neuroprotective effect of diosgenin in a mouse model of diabetic peripheral neuropathy involves the Nrf2/HO-1 pathway. BMC complementary medicine and therapies. 2020;20(1):126.

[32] Yang MY, Fan Z, Zhang Z, et al. MitoQ protects against high glucose-induced brain microvascular endothelial cells injury via the Nrf2/HO-1 pathway. J Pharmacol Sci. 2021;145(1):105–114.

[33] Kosuru R, Kandula V, Rai U, et al. Pterostilbene decreases cardiac oxidative stress and inflammation via activation of AMPK/Nrf2/HO-1 pathway in fructose-fed diabetic rats. Cardiovasc Drugs Ther. 2018;32(2):147–163.

[34] Xiang H, Xue W, Li Y, et al. Knockdown of ANGPTL2 protects renal tubular epithelial cells against hypoxia/reoxygenation-induced injury by suppressing TLR4/NF-κb signaling pathway and activating Nrf2/HO-1 signaling pathway. Cell Transplant. 2020;29:963689720946663.

[35] Wu Y, Xia ZY, Zhao B, et al. (-)-Epigallocatechin-3-gallate attenuates myocardial injury induced by ischemia/reperfusion in diabetic rats and in H9c2 cells under hyperglycemic conditions. Int J Mol Med. 2017;40(2):389–399.

[36] Zheng W, Li T, Wei J, et al. Identification of miR-145 as a regulator of the cardiomyocyte inflammatory response and oxidative stress under hyperglycemia. Exp Ther Med. 2021;21(5):467.

[37] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25(4):402–408.

[38] Yang X, Jiang J, Zhang C, et al. Baicalein restrains proliferation, migration, and invasion of human malignant melanoma cells by down-regulating colon cancer associated transcript-1. Braz J Med Biol Res = Rev Bras Pesqui Med Biol. 2019;52(12):e8934.

[39] Zhou Y, Huang Y, Hu K, et al. HIF1A activates the transcription of lncRNA RAET1K to modulate hypoxia-induced glycolysis in hepatocellular carcinoma cells via miR-100-5p. Cell Death Dis. 2020;11(3):176.

[40] Noman MZ, Desantis G, Janji B, et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211(5):781–790.

[41] Amini N, Sarkaki A, Dianat M, et al. Protective effects of naringin and trimetazidine on remote effect of acute renal injury on oxidative stress and myocardial injury through Nrf-2 regulation. Pharmacol Rep. 2019;71(6):1059–1066.

[42] Liu L, Gan S, Li B, et al. Fisetin alleviates atrial inflammation, remodeling, and vulnerability to atrial fibrillation after myocardial infarction. Int Heart J. 2019;60(6):1398–1406.

[43] Wung BS, Cheng JJ, Hsieh HJ, et al. Cyclic strain-induced monocyte chemotactic protein-1 gene expression in endothelial cells involves reactive oxygen species activation of activator protein 1. Circ Res. 1997;81(1):1–7.

[44] De Keulenaer GW, Ushio-Fukai M, Yin Q, et al. Convergence of redox-sensitive and mitogen-activated protein kinase signaling pathways in tumor necrosis factor-alpha-mediated monocyte chemoattractant protein-1 induction in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2000;20(2):385–391.

[45] Chandraaskar B, Mitchell DH, Colston JT, et al. Regulation of CCAAT/Enhancer binding protein, interleukin-6, interleukin-6 receptor, and gp130 expression during myocardial infarction/reperfusion. Circulation. 1999;99(3):427–433.

[46] Blum A, Sclarovsky S, Behavia E, et al. Levels of T-lymphocyte subpopulations, interleukin-1 beta, and soluble interleukin-2 receptor in acute myocardial infarction. Am Heart J. 1994;127(5):1226–1230.

[47] Liu L. Evaluation on the levels of oxidative stress, inflammatory indices and efficacy of lyophilized recombinant human brain natriuretic peptide in patients with myocardial Ischemia. Medical Innovation of China. 2018;15(9):14–18.

[48] Yin Y, Han W, Cao Y. Association between activities of SOD, MDA and Na(+)-K(+)/ATPase in peripheral blood of patients with acute myocardial infarction and the complication of varying degrees of arrhythmia. Hellenic J Cardiol = Hellenike Kardiologike Epitheorese. 2019;60(6):366–371.
[49] Evran B, Karpuzoğlu H, Develi S, et al. Effects of carnosine on prooxidant-antioxidant status in heart tissue, plasma and erythrocytes of rats with isoproterenol-induced myocardial infarction. Pharmacol Rep. 2014;66(1):81–86.

[50] Takano M, Hirose N, Sumi C, et al. ANGPTL2 promotes inflammation via integrin α5β1 in chondrocytes. Cartilage. 2019. 1947603519878242. 10.1177/1947603519878242

[51] Nishiyama S, Hirose N, Yanoshita M, et al. ANGPTL2 induces synovial inflammation via LILRB2. Inflammation. 2021;44(3):1108–1118.

[52] Yang L, Li T, Zha L. Foxc2 alleviates Ox-LDL-induced lipid accumulation, inflammation, and apoptosis of macrophage via regulating the expression of Angptl2. Inflammation. 2020;43(4):1397–1410.

[53] Yang W, Liu W, Yu W, et al. Angptl2 deficiency attenuates paraquat (PQ)-induced lung injury in mice by altering inflammation, oxidative stress and fibrosis through NF-κB pathway. Biochem Biophys Res Commun. 2018;503(1):94–101.

[54] Oike Y, Tian Z, Miyata K, et al. ANGPTL2 - A new causal player in accelerating heart disease development in the aging. Circulation Journal Official Journal of the Japanese Circulation Society. 2017;81(10):1379–1385

[55] Thorin-Trescases N, Thorin E. Angiopoietin-like-2: a multifaceted protein with physiological and pathophysiological properties. Expert Rev Mol Med. 2014;16. 10.1017/erm.2014.19

[56] Siow RC, Ishii T, Mann GE. Modulation of antioxidant gene expression by 4-hydroxynonenal: atheroprotective role of the Nrf2/ARE transcription pathway. Redox report: communications in free radical research. 2007;12(1):11–15

[57] Kolamunne RT, Dias IH, Vernallis AB, et al. Nrf2 activation supports cell survival during hypoxia and hypoxia/reoxygenation in cardiomyoblasts; the roles of reactive oxygen and nitrogen species. Redox Biol. 2013;1(1):418–426.

[58] Fourquet S, Guerouis R, Biard D, et al. Activation of Nrf2 by nitrosative agents and H2O2 involves KEAP1 disulfide formation. J Biol Chem. 2010;285(11):8463–8471.

[59] Yu H, Shi L, Zhao S, et al. Triptolide attenuates myocardial ischemia/reperfusion injuries in rats by inducing the activation of Nrf2/HO-1 defense pathway. Cardiovasc Toxicol. 2016;16(4):325–335.

[60] Bai L, Shi W, Liu J, et al. Protective effect of pilose antler peptide on cerebral ischemia/reperfusion (I/R) injury through Nrf-2/OH-1/NF-kB pathway. Int J Biol Macromol. 2017;102:741–748.

[61] He W, Su Q, Liang J, et al. The protective effect of nicorandil on cardiomyocyte apoptosis after coronary microembolization by activating Nrf2/HO-1 signaling pathway in rats. Biochem Biophys Res Commun. 2018;496(4):1296–1301.

[62] Zhao SM, Gao HL, Wang YL, et al. Attenuation of high glucose-induced rat cardiomyocyte apoptosis by Exendin-4 via intervention of HO-1/Nrf-2 and the PI3K/AKT signaling pathway. Chin J Physiol. 2017;60(2):89–96.

[63] Li H, Yao W, Irwin MG, et al. Adiponectin ameliorates hyperglycemia-induced cardiac hypertrophy and dysfunction by concomitantly activating Nrf2 and Brg1. Free Radic Biol Med. 2015;84:311–321.